ARTICLE | Financial News
Affimed subsidiary raises $14M, unveils Janssen deal
July 16, 2013 12:50 AM UTC
Affimed Therapeutics AG (Heidelberg, Germany) said its U.S. subsidiary Amphivena Therapeutics Inc. closed $14 million in a series A round led by MPM Capital. Aeris Capital and Affimed also participated. Amphivena is developing a preclinical, bispecific, tetravalent antibody based on Affimed's TandAb technology to treat hematological tumors. MPM Capital's Luke Evnin and Phil Gutry and Aeris' Frank Muhlenbeck will join Amphivena's board, along with Affimed CEO Adi Hoess. ...